BURLINGTON, Ontario–(BUSINESS WIRE)–Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG), a global renewable fuels leader, is pleased to announce that the first tranche of the previously announced equity investment of C$40.8 million (the “Strategic Investment”) from Marny Investissement SA (“Marny”) has closed with the issuance of 31,250,000 units of the Company (“Units”) for gross proceeds of C$12.5 million, immediately following entry by the parties into an amendment agreement.
Each Unit consists of one subordinate voting share of the Company (each a “Subordinate Voting Share”) and 1/5 of one Subordinate Voting Share purchase warrant of the Company (each a “Warrant”). Each Warrant entitles the holder to purchase one additional Subordinate Voting Share at an exercise price of C$0.80 for a period of three years following the date hereof.
In connection with the closing of the first tranche of the Strategic Investment, Ronen Kantor, a nominee of Marny, has been appointed to the Company’s board of directors to fill the vacancy created by the resignation of Alan Viterbi. The Company would like to sincerely thank Alan for his service and contributions to the Company.
Pursuant to the amendment agreement, the remainder of the Strategic Investment is now expected to close as follows: (i) the second tranche of 34,000,000 Units for gross proceeds of C$13.6 million will close no later than March 15, 2024; and (ii) the third tranche of 36,750,000 Units for gross proceeds of C$14.7 million will close no later than March 15, 2024. The closing of second and third tranches remain subject to a limited number of customary conditions.
Please refer to the Company’s news releases dated December 18, 2023, January 2, 2024, January 19, 2024, and January 25, 2024, for more information with respect to the Strategic Investment.
About Marny
Marny is a Luxembourg-based holding company which focuses on investment properties in central and eastern Europe. Marny invests in high-quality projects that utilize advanced technology and materials and through Marny’s collaborations with its partners it ensures that its investments are well-managed and yield maximum value.
About Anaergia
Anaergia was created to eliminate a major source of greenhouse gases (“GHGs”) by cost effectively turning organic waste into renewable natural gas (“RNG”), fertilizer and water through the use of proprietary technologies. With a track record of delivering innovative projects, Anaergia is uniquely positioned to provide solutions to today’s most pressing resource recovery challenges using a broad portfolio of proven technologies and multiple project delivery methods. Anaergia is one of the world’s only companies with a proprietary portfolio of end-to-end solutions that integrate solid waste processing as well as wastewater treatment with organics recovery, high efficiency anaerobic digestion, RNG production and recovery of fertilizer and water from organic residuals. The combination of these technologies enhances carbon-negative biogas, clean water and natural fertilizer production, utilizes a minimized footprint and lowers waste and wastewater treatment costs and GHG emissions.
For further information please see: www.anaergia.com
Forward-Looking Statements
This news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia’s current expectations regarding future events, including but not limited to, statements regarding the closing of the remaining tranches of the Strategic Investment and the release of Units thereunder upon Anaergia’s receipt of the gross proceeds and the timing thereof. Forward-looking information is based on a number of assumptions, including, but not limited to, the timeliness of Anaergia’s receipt of the gross proceeds; the ability of the parties to satisfy the conditions required to close the remaining tranches of the Strategic Investment; the Company’s ability to meet its financing and liquidity requirements on a continuing basis. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, but are not limited to, risk related to any unexpected delay in Anaergia’s receipt of the gross proceeds; counterparty risk exposure and the risk that one or more of the tranches of the Strategic Investment may not be completed or may not be completed in a timely manner; the risk that any enforcement actions taken by Anaergia and/or the preservation of all other legal rights and remedies available to it may be unsuccessful; and the factors discussed under “Risk Factors” in the Company’s annual information form for the fiscal year ended December 31, 2022 and under “Risks and Uncertainties” in the Company’s most recent management’s discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia’s operations or financial results are included in Anaergia’s reports on file with Canadian regulatory authorities.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States or other jurisdiction in which such offer, solicitation or sale would be unlawful.
Contacts
For media and/or investor relations: IR@Anaergia.com
